《《Methanogens in ice cores 2016》.pdf

Current Topics FDA, Producers Moving yields in MDCK cells, providing a “fa- MDCK cells, he says, noting that this toward Mammalian vorable ratio of virus to impurities,” approach provides a “quantitative Cell-Based Flu Vaccines thus making this approach to making conceptual framework for estimating vaccines “economically feasible,” upper bounds on potential risks.” Manufacturers and officials of the adds Jeroen Medema of Solvay, who One unknown is whether MDCK Food and Drug Administration (FDA) also spoke during the November advi- cells are not only tumorigenic, but are planning a major shift in how sub- sory session. His company recently also oncogenic—meaning they might unit influenza vaccines are pro- built a facility in the Netherlands, in contain agents that “transform the duced—discarding chicken eggs in fa- which MDCK cells are being used to cells of the injected species into neo- vor of cultured mammalian cells produce flu viruses for an experimen- plastic cells that grow into tumors,” (Microbe, January 2006, p. 4). Several tal vaccine. In the Solvay process, the says Krause’s colleague Andrew MDCK cells are grown on microcarri- Lewis. If the new vaccines were to factors are adding momentum to this ers within bioreactors. European reg- cause such unexpected types of tu- pending shift, including concerns over ulatory officials granted the company mors in animal tests, he suggests, it pandemic flu, a pledge by President